Excalibur Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.26M Buy
151,843
+963
+0.6% +$25.6K 1.53% 14
2025
Q4
$3.76M Buy
150,880
+5,212
+4% +$131K 1.35% 15
2025
Q3
$3.71M Sell
145,668
-4,379
-3% -$108K 1.35% 17
2025
Q2
$3.64M Sell
150,047
-1,232
-0.8% -$28.7K 1.36% 16
2025
Q1
$3.83M Sell
151,279
-2,357
-2% -$61.7K 1.51% 13
2024
Q4
$4.08M Sell
153,636
-8,742
-5% -$237K 1.62% 11
2024
Q3
$4.7M Sell
162,378
-1,958
-1% -$57.1K 1.79% 9
2024
Q2
$4.6M Buy
164,336
+3,090
+2% +$85.1K 1.88% 9
2024
Q1
$4.47M Buy
161,246
+3,026
+2% +$84K 1.89% 9
2023
Q4
$4.56M Sell
158,220
-30
-0% -$907 2.14% 8
2023
Q3
$5.25M Buy
158,250
+3,878
+3% +$137K 2.73% 7
2023
Q2
$5.66M Buy
154,372
+770
+0.5% +$30K 2.88% 6
2023
Q1
$6.27M Sell
153,602
-26
-0% -$1.12K 3.25% 5
2022
Q4
$7.87M Sell
153,628
-643
-0.4% -$30.8K 4.11% 2
2022
Q3
$6.75M Buy
154,271
+1,476
+1% +$71.7K 3.78% 4
2022
Q2
$8.01M Sell
152,795
-2,143
-1% -$109K 4.17% 3
2022
Q1
$8.02M Sell
154,938
-877
-0.6% -$45.5K 3.48% 4
2021
Q4
$9.2M Sell
155,815
-1,211
-0.8% -$60K 3.71% 4
2021
Q3
$6.75M Sell
157,026
-2,777
-2% -$123K 2.96% 6
2021
Q2
$6.26M Buy
159,803
+2,931
+2% +$114K 2.83% 9
2021
Q1
$5.68M Buy
156,872
+5,191
+3% +$184K 2.8% 9
2020
Q4
$5.58M Sell
151,681
-12,143
-7% -$445K 3% 8
2020
Q3
$5.7M Sell
163,824
-9,760
-6% -$342K 3.46% 7
2020
Q2
$5.38M Buy
173,584
+2,879
+2% +$97.8K 3.59% 7
2020
Q1
$5.29M Buy
170,705
+7,033
+4% +$240K 4.08% 7
2019
Q4
$6.08M Sell
163,672
-697
-0.4% -$24.8K 3.98% 7
2019
Q3
$5.6M Buy
164,369
+5,609
+4% +$204K 5.03% 4
2019
Q2
$6.53M Sell
158,760
-4,626
-3% -$184K 6.01% 3
2019
Q1
$6.58M Sell
163,386
-2,065
-1% -$82.7K 6.21% 2
2018
Q4
$6.85M Sell
165,451
-4,943
-3% -$205K 6.92% 2
2018
Q3
$7.13M Sell
170,394
-10,324
-6% -$397K 6.09% 2
2018
Q2
$6.22M Sell
180,718
-1,942
-1% -$66.4K 4.95% 4
2018
Q1
$6.15M Buy
182,660
+725
+0.4% +$24.9K 5% 5
2017
Q4
$6.25M Sell
181,935
-3,837
-2% -$131K 5.25% 5
2017
Q3
$6.29M Sell
185,772
-3,968
-2% -$128K 5.35% 5
2017
Q2
$6.05M Sell
189,740
-1,605
-0.8% -$50.6K 5.42% 5
2017
Q1
$6.21M Buy
191,345
+2,454
+1% +$77.4K 5.53% 4
2016
Q4
$5.82M Buy
188,891
+2,483
+1% +$75.8K 5.3% 6
2016
Q3
$5.99M Sell
186,408
-9,708
-5% -$325K 5.68% 5
2016
Q2
$6.55M Sell
196,116
-1,112
-0.6% -$35.5K 5.63% 5
2016
Q1
$5.55M Buy
197,228
+330
+0.2% +$9.43K 4.97% 6
2015
Q4
$6.03M Sell
196,898
-1,723
-0.9% -$54.2K 5.61% 5
2015
Q3
$5.92M Buy
198,621
+4,975
+3% +$160K 5.92% 5
2015
Q2
$6.16M Buy
193,646
+4,198
+2% +$137K 5.76% 5
2015
Q1
$6.25M Sell
189,448
-12,379
-6% -$394K 6.05% 5
2014
Q4
$5.96M Sell
201,827
-3,177
-2% -$91.1K 6.01% 5
2014
Q3
$5.75M Buy
205,004
+1,305
+0.6% +$36.6K 5.91% 5
2014
Q2
$5.74M Buy
203,699
+5,507
+3% +$157K 5.99% 5
2014
Q1
$6.04M Sell
198,192
-6,693
-3% -$200K 6.62% 5
2013
Q4
$5.95M Sell
204,885
-3,578
-2% -$104K 6.49% 5
2013
Q3
$5.68M Buy
208,463
+8,980
+5% +$244K 6.67% 5
2013
Q2
$5.3M Buy
+199,483
New +$5.51M 6.58% 5

Other funds holding PFE

Excalibur Management's PFE Position: Q1 2026 in Review

Excalibur Management increased its Pfizer (PFE) stake by 0.64% in Q1 2026, buying an estimated $25.6K and bringing the position to 151,843 shares worth $4.26M. The position accounts for 1.53% of the portfolio, ranked #14.

Excalibur Management first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $9.2M in Q4 2021. 2,938 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Excalibur Management held 151,843 shares of Pfizer worth $4.26M as of Q1 2026.
  • Excalibur Management bought 963 Pfizer shares in Q1 2026, an estimated $25.6K.
  • Pfizer made up 1.53% of Excalibur Management's portfolio in Q1 2026, its #14 holding.
  • Excalibur Management first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Excalibur Management's Pfizer position peaked at $9.2M in Q4 2021.
  • 2,938 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Excalibur Management's 13F filing for Q1 2026, filed 5 May 2026.